A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors

This early-phase trial is testing a new immunotherapy drug called GI-108 — which both targets a molecule that suppresses the immune system (CD73) and activates immune cells (IL-2) — in people with advanced or metastatic solid tumors that have not responded to standard treatments. **You may be eligible if...** - You are 18 or older with an advanced or metastatic solid tumor - You have measurable disease and are in reasonable physical condition (ECOG 0–1) - Side effects from any prior cancer treatment have mostly resolved - If you have HIV, it must be well-controlled on antiretroviral therapy **You may NOT be eligible if...** - You have active brain metastases or another active cancer - You have active hepatitis B, hepatitis C, or active tuberculosis - You have chronic liver disease or cirrhosis (unless from liver metastases) - You have an active autoimmune disease requiring systemic treatment - You have had a serious infection within the past 4 weeks Talk to your doctor to see if this trial is right for you.